I am a doctor-scientist working at the intersection of precision medicine, oncology strategy, and large-scale healthcare systems. My focus is not limited to individual treatments or technologies, but on how medical platforms are designed, integrated, and scaled to deliver measurable clinical and systemic impact.
Huang Shiyan is a Singaporean physician-scientist and healthcare executive with over 15 years of multinational experience spanning clinical medicine, biomedical research, and healthcare strategy.
Educated at the National University of Singapore and the University of Oxford, her work integrates clinical rigor with advanced research in genomics and precision oncology.
Modern healthcare systems are constrained less by scientific breakthroughs than by structural inefficiencies. Precision medicine is often framed as a technological challenge, yet its real bottleneck lies in system design, data interoperability, clinical workflows, and reimbursement logic.
Artificial intelligence and genomic data create value only when they are embedded directly into clinical decision-making rather than operating as external tools.
The differences in efficiency between Asian and European healthcare systems ultimately reflect governance models, incentive alignment, and how clinical, technological, and financial layers are coordinated.
My work centers on building precision oncology platforms, scaling genomic diagnostics across clinical networks, integrating clinical data with AI-driven systems, and improving cross-border healthcare efficiency. Across these domains, the emphasis is on creating platforms that are clinically meaningful, operationally viable, and scalable across regions.
My path from clinical medicine to research, and from research into industry, was driven by a consistent question: how discoveries move from isolated excellence to population-level impact.
Clinical training revealed the limits of siloed care, research exposed the gap between innovation and application, and industry provided the tools to scale solutions.
Understanding capital, systems, and incentives became essential to translating medical science into sustainable healthcare infrastructure.
Leading multinational healthcare strategy, genomics platforms, AI-driven systems, and investments exceeding USD 600 million.
Medical training at the National University of Singapore, doctoral research in Biomedical Sciences at the University of Oxford, and executive business education at London Business School.
Design and leadership of translational clinical programs integrating genomics, biomarkers, and precision diagnostics into real-world care pathways.
Projects span oncology, complex disease management, and AI-enabled clinical decision systems, with a focus on scalability, regulatory alignment, and patient-centered outcomes.
Executive leadership at the intersection of medicine, research, and healthcare infrastructure development, with board-level responsibilities spanning multinational health technology organizations.
Experience includes strategic governance, clinical oversight, investment evaluation, and long-term platform scaling across diverse healthcare systems.
Focused on translating scientific and clinical innovation into scalable healthcare systems through governance design, data integration, and incentive-aligned infrastructure.
Invited speaker at international medical and life sciences conferences, healthcare innovation forums, and academic institutions.
Recipient of academic and professional recognitions for translational research, clinical leadership, and healthcare strategy.
Active member of international medical, scientific, and healthcare leadership organizations across Asia and Europe.
This platform is intended for academic, clinical, and strategic healthcare collaborations.
For official company information, please refer to Inari Medical .